Harmony Biosciences (HRMY) Tops Q1 EPS by 16c, Revenues Beat

Harmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $0.13, $0.16 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $59.7 million versus the consensus estimate of $57.07 million.

First Quarter 2021 Highlights:

• Net product revenue of $59.7 million for the quarter ended March 31, 2021;
• Significant growth in WAKIX sales, supported by the addition of the cataplexy indication, which strengthens the overall benefit/risk profile;
• Increased average number of patients on WAKIX and number of unique healthcare professionals who have prescribed WAKIX since launch;
• Net income positive for the first quarter of 2021; and
• Cash and cash equivalents of $141.2 million.

“We are off to a very strong start in 2021 with the continued demand for WAKIX® driving strong first quarter net revenues,” stated John C. Jacobs, President and Chief Executive Officer of Harmony. “We saw growth in the average number of patients on WAKIX and net revenue, putting us in the position of profitability this quarter, for the first time in our company history, demonstrating our resilience and performance through the lingering pandemic and anticipated seasonal payer dynamics in Q1.

As a first-in-class medication with a novel mechanism of action and differentiated product profile, WAKIX remains the only FDA approved product for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy that is not scheduled as a controlled substance, filling a significant unmet medical need for patients living with narcolepsy. With a strong cash position and positive cash flow, we are well positioned to continue supporting our commercialization efforts for WAKIX, advance and expand our clinical programs, and to consider the acquisition of complementary assets to build out our product pipeline.”

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• World Kinect Corporation (WKC) Misses Q1 EPS by 2c, Misses on Revenue
• Bristol-Myers Squibb (BMY) stock slips despite earnings beat